These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12716274)

  • 1. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
    Lane HY; Chang YC; Cheng YC; Liu GC; Lin XR; Chang WH
    J Clin Psychiatry; 2003 Mar; 64(3):316-20. PubMed ID: 12716274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of patient-related variables on risperidone efficacy for acutely exacerbated schizophrenia: analyses with rigorous statistics.
    Lane HY; Chang YC; Chiu CC; Chen TT; Lee SH; Chang WH
    J Clin Psychopharmacol; 2002 Aug; 22(4):353-8. PubMed ID: 12172333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.
    Lane HY; Chang YC; Chiu CC; Lee SH; Lin CY; Chang WH
    Psychopharmacology (Berl); 2004 Apr; 172(4):393-9. PubMed ID: 14663551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
    Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
    J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
    Glick ID; Lemmens P; Vester-Blokland E
    Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
    Mozes T; Ebert T; Michal SE; Spivak B; Weizman A
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):393-403. PubMed ID: 16958565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    J Clin Psychopharmacol; 2005 Aug; 25(4):293-300. PubMed ID: 16012270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
    Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
    Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
    J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
    J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.